



Strategies for Stem Cell-Based Therapy for Inner Ear Cochlear Regeneration

Ali Asghar Peyvandi¹, Hojjat-Allah Abbaszadeh^{2,1,3}, Shahrokh Khoshsirat¹, Alireza Zali⁴, Somayeh Niknazar^{4,1*} 

1. Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2. Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3. Department of Anatomical Sciences and Biology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4. Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

The organ of Corti of mammals has an organized structure in which row of inner and outer hair cells (HCs) are enclosed within the numerous cells on the basilar membrane. Given the prevalence of sensorineural hearing loss due to aging and acoustic insult, it is highly desirable to develop a protocol that produces cochlear sensory cells and their associated spiral sensory neurons as a tool to advance understanding of inner ear development. The replacement of damaged auditory neurons holds promise for significantly improving clinical outcomes in deaf patients. Cell therapy is one of the treatment options for deafness. The progress in cell therapy and reprogramming techniques has opened avenues to stimulate either endogenous or transplanted stem cells, aiming to replace and repair damaged inner ear HCs and restore auditory function. In fact, current research focuses on generating functional HCs. Various approaches are being explored to regenerate auditory HCs and facilitate neural connections. Here is an overview of existing experimental culture setups for the HCs and auditory neurons regeneration and their potential treatment for hearing disorders.

Keywords:

Cell therapy

Hair cells

Spiral ganglion neurons

Regeneration

Introduction

Hair cells (HCs) and auditory neurons in the inner ear work together to send acoustic information to the brain (Hyakumura et al., 2019). A complex cell arrangement during embryonic development in a precisely coordinated spatiotemporal manner is required for proper function of the inner ear of vertebrates. HCs are located in both the auditory and vestibular regions of the inner ear (Menendez et al., 2020). The primary cause of deafness often stems from the death and/or dysfunction of HCs within the organ of Corti (Khoshsirat et al., 2021). HCs

are precisely arranged, with a single row of inner HCs on the medial side of the epithelium and three rows of outer HCs positioned more laterally within the organ of Corti (Fig 1). Supporting cells, including Hensen's cells, Deiters' cells, pillar cells and phalangeal cells, intermingle with HCs in the cochlea. HCs are susceptible to degradation with age and can sustain damage from loud noises, and treatments like those used in infections or cancer chemotherapy. In mammals, lost HCs cannot be repaired or replaced. While extensively studied in mice, studying HCs poses challenges due to their limit-

* Corresponding author: Somayeh Niknazar, niknazar.somayeh@gmail.com, niknazar@sbmu.ac.ir

Received 13 June 2022; Revised from 13 December 2022; Accepted 9 January 2023

Citation: Peyvandi A.A., Abbaszadeh H, Khoshsirat S, Zali A, Niknazar. S. Strategies for Stem Cell-Based Therapy for Inner Ear Cochlear Regeneration. *Physiology and Pharmacology* 2023; 27: 331-344. <http://dx.doi.org/10.61186/phypha.27.4.331>




FIGURE 1. The anatomy of the human ear and cochlear partition. (A) The human ear consists of three primary components: the outer, middle, and inner ear. (B) In the cochlea, a cross-sectional view reveals three ducts: the scala vestibuli, scala media (or cochlear duct), and the scala tympani. Scala media, an endolymph-filled compartment includes sensory hair cells (Adapted from Noback 1967). (Noback, 1967; Kandel et al., 2000).

ed numbers in the inner ear and their deep location within the temporal bone. Researchers are looking for ways to grow HCs in the laboratory to better understand their functionalities and the contributing factors to their degradation and loss (Menendez et al., 2020). Several experimental studies have shown the regeneration of auditory neurons through the application of exogenous neurotrophins in cases of sensorineural hearing loss (Gillespie and Shepherd, 2005; Shepherd et al., 2008; Bader et al., 2010; Chen, 2011; Ortiz-Marquez et al., 2013). However, the neuroprotective effect of neurotrophic factors was not observed after treatment (Momeni et al., 2011). Long-term delivery of exogenous neurotrophins to the cochlea using pump-based systems presents challenges due to increased infection risks associated with device reloading or replacement, commonly applied in laboratory animal studies (Chuang, 2012). In regarding to these difficulties, researchers are developing multiple strategies to direct the differentiation of progenitor and

exogenous cells towards the regeneration of functional HCs and auditory neurons (Chen et al., 2012; Okano and Kelley, 2012; Peyvandi et al., 2018a; Peyvandi et al., 2018b). Cell therapy holds promise as a treatment for sensorineural hearing loss, potentially enabling the repair or replacement of lost HCs. Utilizing various sources of adult and embryonic stem cells in monoculture has been investigated for repairing or replacing injured HCs (Zengler et al., 2002). Interactions and signal transduction between developing tissues play important roles in the regulation of differentiation *in vivo*. Due to cellular signaling pathways complexity, it is often difficult to completely mimic this environment *in vitro* (Peyvandi et al., 2018a; Peyvandi et al., 2018b). Efforts have been made to derive auditory neurons from stem cells established *in vitro* or through co-culture approaches, aiming to repair or regenerate hearing loss caused by sensorineural issues (Coleman et al., 2007; Sambandam, 2018). The purpose of this study is to review the




FIGURE 2. Biological approaches for cochlear regeneration in sensorineural hearing loss

induction procedures for stem cell differentiation into cochlear HCs or auditory neurons, offering a potential therapeutic approach for treating deafness.

Literature Search

Papers were collected from Web of Science, PubMed, Scopus, and Google Scholar electronic databases from 2000 to 2022 to discuss the development of cell therapy approaches for damaged cochlear HCs regeneration or replacement which help in resolving deafness. Also, an e-book (1967) was used for schematic illustrations.

Conventional Approaches

Repairing HCs damage is important for maintaining auditory function throughout life, as mammalian HCs do not replace or regenerate. For decades, researchers across the globe have been dedicated to discovering cures for deafness (Nakagawa, 2014). Although cochlear implants have gained popularity for managing hearing loss, they do not cure deafness or restore natural hearing. These devices transform input sounds into electrical stimuli within the Spiral ganglion neurons (Sprinzl and Riechelmann, 2010). Recent biological approaches aiming to regenerate cochlear HCs in mammals offer

promising directions for treating deafness by modulating molecular pathways or through cell transplantation (Steel and Kros, 2001; Li et al., 2004) (Fig 2).

Cochlear Implant

A cochlear implant (CI) is a small electronic device designed to electrically stimulate the SGNs within the cochlea of deaf people, enabling them to receive and interpret sound. By bypassing the normal auditory transmission pathway through hair cells, a CI provides direct electrical stimulation to the SGNs. In fact, it bypasses the damaged part of the cochlea and directly stimulates the remaining auditory neurons. While cochlear implants do not cure or restore hearing, they help people with severe or complete deafness in perceiving sound (Ramsden, 2002).

Growth Factors Therapy

Growth factors, a class of secretory proteins, play critical roles in cell survival, proliferation, and differentiation, particularly in various conditions aimed at differentiating auditory HCs (Bakhtiarzadeh et al., 2018; Mahmoudian-Sani et al., 2018). Three families of growth factors, including fibroblast growth factor

(FGF), neurotrophin (NT), and insulin growth factor-1 (IGF-1), are involved in otic neurogenesis. In this regard, auditory neurons can connect to the sensory mechanoreceptors, HCs, and central nervous system of the ear (Alsina et al., 2003). Neurotrophic factors are critical for the developing auditory system and innervation during development. In addition, they are necessary for the survival and maintenance of SGNs in adulthood. Treatment with neurotrophins protects and prevents cochlear cells from degeneration caused by drugs, noise, or aging (Niknazar et al., 2022) (Mahmoudian-Sani et al., 2018). Simultaneous application of multiple growth factors with neomycin has significant effects in reducing HC loss. Among these, epidermal growth factor (EGF) has proven effective in supporting the survival of outer HCs (Lou et al., 2015). EGF receptor transcripts are upregulated in neomycin-treated cochlear epithelium in 3-day-old rats, that increases mammalian neonatal HC replacement process following neomycin induced HC toxicity (Zine et al., 2000). Furthermore, interventions involving brain derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) have enhanced the survival and function of SGNs in guinea pig models of hearing loss (Shinohara et al., 2002). Studies administering glial-derived neurotrophic factor (GDNF) to the inner ear of hearing-impaired animals have reported protective effects on SGNs survival and electrical responsiveness (Maruyama et al., 2008; Fransson et al., 2010). Current challenges associated with neurotrophic factors therapy is how to deliver them to the cochlea. Several methods such as osmotic mini-pumps, carrier-based delivery, or encapsulated cell targeted delivery have been applied. In addition, the long-term effects of exogenous neurotrophin delivery pose challenges due to a heightened risk of infection (Shinohara et al., 2002; Agterberg et al., 2009; Pettingill et al., 2011).

Totally, growth factors are important factors during the development of the auditory system and ganglion cell innervation. They are also essential for maintaining adult SGNs, protecting neuronal populations from injury, or stimulating neuronal regeneration and repair after injury.

Gene Therapy

Gene therapy, utilizing exogenous DNA delivery or genome editing agents to the cochlea, is another option to treat hearing disorders. So far, numerous vectors from

different virus families such as adenovirus, adeno-associated virus or lentivirus have been tested. Protective effects of adenovirus-mediated overexpression of GDNF against gentamicin ototoxicity have been shown by Suzuki et al (Suzuki et al., 2000). Nonviral vector systems, including plasmids and lipid-covered packages are also alternatives methods for gene delivery. As well, electroporation technology has been developed to manipulate gene expression in postnatal rat cochlear explants using the pCligGFPAtoh1 vector (Zheng and Gao, 2000). In addition, CRISPR-associated protein 9 (CRISPR/Cas9) has greatly enhanced genome editing efficiency in modifying mutant alleles for treating hearing loss in animal models. Currently, the combination of iPSC modeling and CRISPR / Cas9 gene editing shows great potential for gene and stem cell therapies in hearing loss treatment (Nourbakhsh et al., 2021).

The closed space of the inner ear makes gene or drug delivery highly efficient compared to systemic delivery, where large doses are often required to reach the inner ear. Recent advancements in inner ear gene therapy show increased accessibility, offering promising avenues for further research. Continuous efforts to improve cochlear gene delivery methods hold the potential to establish gene therapy as a viable treatment for hearing loss.

Cell Therapy

Stem cells in several mammalian tissues has the potential to self-regenerate and aid in the repair of injured tissue. Investigations into stem cell therapy for addressing hearing loss primarily concentrate on their potential to develop and function as HCs. Researchers are developing multiple strategies to guide exogenous and progenitor cells towards the regeneration of functional HCs or auditory neurons within the inner ear (Niemeyer et al., 2011; Goers et al., 2014; Krinner and Roeder, 2014), (Table 1).

Strategies to Induce Otic Cell types From Stem Cells/Endogenous Stem Cells

HCs in the inner ears of non-mammalian vertebrates, including birds, amphibians, and fish, exhibit a lifelong ability to regenerate (Warchol et al., 1993; Goers et al., 2014). In contrast, the adult mammalian auditory system fails to regenerate damaged hair cells, resulting in permanent hearing loss. Recent studies, however, have demonstrated the differentiation and regeneration of

TABLE 1: The effect of exogenous stem cells in the treatment of hearing impairment in animal models. Neural stem cells (NSCs), Bone marrow mesenchymal stem cells (BM-MSCs), Rosens thatal's canal (RC), Auditory brainstem responses (ABR) and distortion product otoacoustic emissions (DPOAE). Spiral ganglion neurons (SGNs), Auditory nerve (AN), Human otic progenitor cells (hOPCs).

Type of Stem cells	Model	Transplantation Delivery Approach	Target	Outcome of Cell therapy	References
Neural Stem Cells	Rat Hippocampus-derived NSCs	Cochlear wall or round or oval windows	Cochlear tissue	Transplanted NSCs were integrated into the organ of Corti and some HSCs developed into hair cells.	(Ito et al., 2001)
	Mouse NSCs	Cochleostomy	Cochlear neurons or sensory epithelia	Transplanted NSCs survive and differentiate in the injured inner ear	(Hu et al., 2005)
	Rat olfactory epithelium NSCs (oe-NSCs)	Retroauricular	SGNs in Rosenthal's canal	Restoration of hearing function (ABR). Implanted oe-NSCs survived and migrated into RC around SGNs.	(Xu et al., 2016)
	Mouse NSCs	Round window	SGNs	Grafted NSCs differentiate into neurons in the modiolus and restore spiral ganglion neurons	(Tamura et al., 2004)
	Mouse NSCs	Round window	Cochlear tissue	NSCs integrated into the cochlear tissue and differentiated into a several of cochlear cell types	(Parker et al., 2007)
	Human BM-MSCs	Intravenous injection	Spiral ganglion area	Migration of cells into the cochlea was associated with the BDNF expression	(Choi et al., 2012)
	Rat BM-MSCs	Transtympanic delivery	Cochlear tissue	Hearing normal function (ABR and DPOAE)	(Mittal et al., 2020)
Mesenchymal Stem Cells	Rat Model of Acute Sensorineural Hearing Loss	lateral semicircular canal	Cochlear fibrocytes	Improved hearing recovery (ABR) and repaired interrupted gap junction network	(Kamiya et al., 2007)
	C57BL/6J Mice	Posterior semicircular canal	Cochlear fibrocytes	Differentiation of transplanted MSCs into fibrocyte-like cells without adverse side effects on hearing function	(Kasagi et al., 2013)
	Guinea pig Model of Acute Sensorineural Hearing Loss	Brachial vein	SGNs	Increase in number of Spiral ganglion neurons and improvement of auditory function (ABR and DPOAE)	(Kil et al., 2016)
	Rat Model Of β -tubulin induced autoimmune sensorineural hearing loss	Intraperitoneal	Cochlear Hair cells	improved hearing function (ABR) and protected hair cells	(Yoo et al., 2015)

Type of Stem cells	Model	Transplantation Delivery Approach	Target	Outcome of Cell therapy	References
Induced Pluripotent Stem Cell	Mouse iPSCs	Round window	Cochlear Hair cells	The transplanted OEPs derived from iPSCs differentiated into hair cells. The dendritic endings of native SGNs formed synaptic connections with the adjacent regenerated hair cells.	(Chen et al., 2018)
	Human iPSCs	Cochleostomy	Cochlear Tissue	The iPSC-derived-hOPCs were incorporated into the ototoxin-exposed cochlear sensory epithelium, and partially differentiated into cells expressing initial HC and supporting cell markers.	(Lopez-Juarez et al., 2019)
	Human iPSCs	Cochleostomy	SGNs	Human iPSC-derived neurons contributed to the settlement of transplant-derived neurons expressing VGLUT1 in guinea-pig cochleae	(Ishikawa et al., 2017)
	Mouse iPSCs	Cochleostomy	Cochlear Tissue	Transplanted iPSCs did not show a therapeutic effect	(Gökcan et al., 2016)
	Mouse ESCs	Round window	SGNs	Small number of transplanted ESCs differentiate into mature neuron- and glia-like cells	(Lang et al., 2008)
Embryonic Stem Cells	Mouse ESCs	Round window	Auditory primary neurons, Spiral ganglion neurons.	functional restoration of spiral ganglion neurons (ABR)	(Okano et al., 2005)
	tau-GFP mouse ESCs	Scala tympani	AN	Cells were detected in scala tympani, modiolus, AN trunk and the brain stem.	(Palmgren et al., 2012)
	mouse ESCs	Round window	SGNs	A small number of ESCs survived in the deafened cochlea for up to 4 weeks, without eliciting an inflammatory response.	(Coleman et al., 2006)

HCs from endogenous inner ear stem cells. During this regeneration process, endogenous stem cells can differentiate into HCs through a combination of mitotic and non-mitotic mechanisms, triggered by signals sent by dying hair cells (Li et al., 2003a; Oshima et al., 2007).

Research has also revealed the innate ability of adult mammalian vestibular HCs to self-repair following injury. Notably, apart from the vestibular system, the cochlea of newborn mammals also contains endogenous stem cells (Kelley, 2006; Brigande and Heller, 2009). Therefore, a promising approach to treat SNHL involves either activating endogenous stem cells or inducing genetic modifications in the remaining hair cells. Recent studies have shown that inner ear stem/progenitor cells can be isolated from the neonatal cochlea (Oshima et al., 2007). Moreover, the overexpression of several genes in adult cochlear cells suggests an inherent capacity for repair when stimulated by specific signals (Izumikawa et al., 2005).

The presence of stem cell inside the cochlea raises the hope for the regeneration of inner ear cells. However, the loss of these stem cells postnatally correlates with a decline in regenerative potential and can restrict our ability to stimulate regeneration. Hence, future strategies for regeneration should carefully consider the distribution of endogenous stem cells in the inner ear and whether cells retaining regenerative potential are conserved.

Exogenous Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult cells identified by their non-hematopoietic nature, multipotency, high self-renewal capacity, rapid proliferation rate, differentiation potential, paracrine activity, and ability to migrate to injury sites (Guadix et al., 2017). MSCs derived from sources like bone marrow, blood, adipose tissue, umbilical cord, and placenta which applied in various tissue regeneration studies (Ding et al., 2011). Among these, bone marrow-derived MSCs hold promise for inner ear cell replacement therapy. The differentiation of MSCs into auditory HC-like cells and neuronal cells needs factors such as BDNF, GDNF, neurotrophin-3 (NT-3), and growth factors (Mahmoudian-Sani et al., 2017; Gonmanee et al., 2018; Young et al., 2018). In a study by Sang-Jun Jeon, MSCs obtained from mouse bone marrow were differentiated into sensory HCs. MSCs were first transfected with the transcription fac-

tor EGFP-Math1 and then differentiated into sensory progenitor cells through a two-week culture involving IGF1, EGF, bFGF, NT3, and BDNF. Overexpression of Math1, a key HC development inducer, augmented the expression of HC markers in the sensory epithelium. Co-culture with chick otocyst cells further increased the expression of HC-related markers such as myosin VIIa, p27Kip, Brn3c, jagged2, and Math1, suggesting MSCs' differentiation to inner ear sensory cells (Jeon et al., 2007). It was reported that MSCs derived from rat bone marrow could differentiate into HCs in culture. MSCs were first differentiated into neuron-like cells. Neural differentiation involved culturing BMSCs (at passage 4) in DMEM/F12 supplemented with B27, bFGF, and EGF. For the HC-like cell induction, neural stem cells were cultivated in a serum-free medium comprising DMEM/F12, B27, bFGF (Basic fibroblast growth factor), EGF, and IGF-1 for 14 days, resulting in the detection of HC markers like Myosin VIIA via immunocytochemistry (ICC) assay (Qin et al., 2011; Niknazar et al., 2019). MSCs-based therapies have been widely used in the treatment of various disorders (Wu et al., 2014). Systemic administration of MSCs in noise or drug-induced cochlear damage models triggers abundant neurotrophin release at the injured cochlea site, enhancing the regeneration of auditory HCs and neurons (Choi et al., 2012). In the sensorineural hearing loss model, MSCs transplantation has led to functional hearing recovery by repairing damaged spiral ligament fibroblasts (SLF) and damaged gap junction networks in the cochlear lateral wall, facilitated by the migration and proliferation of MSCs (Kamiya et al., 2007). In young mice cochlea, implanted MSCs migrated and transformed into fibroblast-like cells without affecting auditory function, suggesting that MSCs transplantation could potentially slow or halt the early progression of sensorineural hearing loss (Kasagi et al., 2013).

The application of cell therapy utilizing MSCs for damaged cochlear tissues holds promise for regenerating HCs, SGNs, and spiral ligaments. Indeed, MSCs therapy contribute to slowing the progression of hearing loss.

Neural Stem Cells

Neural stem cells (NSCs) can regenerate themselves and differentiate into various cell types including neurons, oligodendrocytes, and astrocytes (Clarke et al.,

2000; Gage, 2000). Several studies have shown that the use of NSCs in the treatment of SNHL is promising by replacing spiral ganglion neurons or HCs within the inner ear. NSCs were transduced with neurogenin 2 (*ngn2*) before transplantation into both normal and hearing-loss animal cochlea, resulting in notably low survival rates of transplanted cells in the *ngn2*-introduced group (Hu et al., 2005). Another study involved transplantation of adult mouse NSCs into the inner ears of mature guinea pigs to investigate their potential for survival and differentiation into auditory neurons (Carricondo and Romero-Gómez, 2019). Parker et al., revealed that transplanted NSCs in acoustically damaged cochlea migrated throughout the cochlea, expressing markers for HCs and SGNs (Parker et al., 2007). A recent study investigated the therapeutic effect of olfactory epithelium neural stem cells (oeNSC) on noise-induced hearing loss in a rat model. Transplanted oeNSC successfully ameliorated deafness in rats, evidenced by improved auditory brainstem response (ABR) results. SGNs incubation with oe-NSCs led to enhanced release of neurotrophic factors such as NGF and NT-3, indicating the potential of oe-NSCs in upregulating neurotrophic factor expression and thus aiding in recovery (Xu et al., 2016).

Multiple investigations have highlighted the promise of NSCs in SNHL treatment by either replacing damaged inner ear cells or aiding in their repair and regeneration. NSCs exhibit the potential to differentiate into hair cells, supporting cells, and auditory neurons within the inner ear, offering hope for future therapeutic interventions.

Embryonic Stem Cells

Previous study has shown that the differentiation of the otic progenitor cells is independent of external signals from neighboring cells for suitable differentiation (Oshima et al., 2010). In vitro differentiation of human embryonic stem cells into either HCs or sensory neurons is associated with the expression of several well-characterized markers at each stage. However, auditory neuron and sensory cell culturing revealed grand challenges in terms of both culture media and the necessary differentiation factors for alteration of progenitor cells into the specified cell type (Dufner-Almeida et al., 2019). Stem cell-derived murine progenitor cell, whether post-transplant in chicken embryonic ears, within 3D aggregates, or within the presumptive otic progenitor cells, needed

co-culture with mesenchymal stromal cells from the chicken utricle to achieve proper cell morphological maturation (Li et al., 2003b; Koehler et al., 2013). Serum-free media containing supplements like N2 and B27 have shown potential in inducing neural progenitor cells expressing specific markers of ear placode neuroblasts such as *Otx2*, *NeuroD*, *Brn3a*, *Nestin*, *Pax2*, and *Pax8* as a starting point for ESC differentiation (Chen et al., 2012) (Shi et al., 2007; Ronaghi et al., 2014). Studies investigating ESCs for the replacement of HCs and SGNs in inner ear regeneration have utilized various approaches. In early studies, mouse ESCs labeled with green fluorescent protein (GFP) were introduced into the cochlea (Hildebrand et al., 2005). Co-culture of human ESCs with mouse cochlear sensory epithelium in the presence of bone morphogenetic protein 4 (BMP4) was found to be crucial for inducing the expression of markers like *GATA3*, *Peripherin*, *Tropomyosin receptor kinase B (TrkB)*, *TRKC* and *ngn1*, markers of auditory neurons, in some cells (Ronaghi et al., 2014). However, only a small fraction of these cells expressed three more HC-related markers, including *MYO7A*, *MYO15A*, *ATOH1*, and *OTOF (Otoferlin)*. Progenitor cells derived from human ESCs, when differentiated, have demonstrated the ability to mature in mouse organ of corti explants, expressing tubulin and synapsin at the junction field. Sixty days after transplantation of neural progenitor cells that previously differentiated from human ESCs into the base of a gerbil-deafferented cochlea, abundant new neurites protruding towards the apex of the cochlear nerve trunk were detected (Shi et al., 2007).

The potential of ESCs to generate multiple cell types has prompted studies exploring their use in replacing HCs and SGNs for inner ear regeneration. Additionally, being derived from the patient's own cells, ESCs are considered autologous and do not pose the risk of immune rejection.

Induced Pluripotent Stem Cells

Pluripotent stem cells (PSCs) have the ability to remain undifferentiated, self-replicate and differentiate over extended periods (Thomson et al., 1998 thesis). Induced pluripotent stem cells (iPSCs) are shaped through the compelled expression of numerous transgenes, generally a combination of *Sox2*, *c-Myc*, *Oct3/4*, and *Klf4*, which reprogram somatic cell nuclei from human,

monkey, rat, mouse, and canine origins (Nelson et al., 2010). Both hESCs and iPSCs are considered pluripotent. Human iPSCs have been considered as an effective alternative for human ESCs. Thus, the ability of these cells makes them as a viable option for cell-based therapies (Yu and Thomson, 2014). In a study by Oshima et al., HC-like cells derived from murine ES and iPS cells responded to mechanical stimuli. The differentiation of HC-like cells showed no significant difference between ESCs and iPSCs. Both murine ESCs and iPSCs demonstrated the ability to generate otic progenitor cells capable of differentiating into mechanosensory HCs in vitro. These cells expressed specific markers for HCs and responded to mechanical stimulation, similar to the transduction currents of immature HCs (Oshima et al., 2010).

Gunewardene et al., successfully established a neurosensory cell line in vitro using two human foreskin-derived iPSC lines. The step-by-step differentiation process yielded electrophysiologically active sensory neurons, displaying activity patterns resembling those of auditory neurons in early postnatal mice (Gunewardene et al., 2014). In the work by Oshima et al., iPSCs derived from Atonal homolog 1 (Atoh1) / nGFP transgenic mouse fibroblasts were cultured with Smad3 inhibitors, Wnt pathway inhibitors, and IGF1 for five days, followed by exposure to bFGF for three days to induce differentiation into ear progenitor cells (Oshima et al., 2010). These cells then differentiated into HCs by co-culture with mitotically inactivated embryonic chicken utricle stromal cells. However, the overall efficiency of HC differentiation from iPSCs was low, with approximately about 12% of iPSC-derived HCs expressing Myosin VIIA (MYO VIIA), while only 2.6% expressing both MYO VIIA and ESPIN. These iPSC-derived HCs exhibited morphological and electrophysiological characteristics of immature HCs.

Chen et al., also succeeded in obtaining HCs from human iPSCs (Chen et al., 2018). They utilized iPSCs derived from human urinary cells, subjecting them to a HC differentiation protocol similar to ESCs, resulting in the production of HC-like cells with an efficiency of up to 50% (Chen et al., 2012). Another study investigated the effect of mouse iPSCs in a SNHL model by differentiating them into HCs and SGNs within the mouse cochlea. CM-Di1-positive iPSCs were detected in the modiolus and Rosenthal's canal of the cochlea 4 weeks after implantation. Some of these cells expressed mark-

ers of HCs or SGNs. While the transplantation of iPSCs slightly improved the ABR threshold, there was no significant difference between pre- and post-transplant iPSCs. Notably, the transplanted iPSCs were able to migrate and transform into HC-like and SGNs-like cells within the cochlea (Nishimura et al., 2009).

Overall, iPSCs have demonstrated promise in regenerating inner ear cells across various studies (Dufner-Almeida et al., 2019). However, further research is needed to enhance the survival and differentiation of iPSCs in the cochlea for more effective application in hearing loss therapies.

Clinical Application of Stem Cells for Inner ear

The clinical application of stem cells for hearing loss treatment is still in its early stages. Studies examining the transplantation of autologous BM-MSC in patients with SNHL did not yield clinically significant improvements in hearing. However, a 3-year follow-up showed no complications or side effects (Lee et al., 2018). Another study by Baumgartner et al., investigated the effect of autologous umbilical cord stem cells (HUCB) in acquired SNHL in children. The clinical trial involved audiological assessments such as distortion product otoacoustic emissions (OAE), ABR, tympanometry, audiogram, and brain MRI (magnetic resonance imaging) before and after a single intravenous administration of HUCB. Encouragingly, no observed toxicity or complications were reported. Children who received a higher dose of cells exhibited a decline in ABR threshold, alongside increased white matter areas in the primary auditory cortex observed in fractional anisotropy of MRI (Baumgartner et al., 2018).

In addition, current gene therapy research has focused on treating genetic deafness using patient- iPSCs (Nourbakhsh et al., 2021). Another study showed that hiPSC lines reprogrammed using non-integrated mRNA expressed ear markers PAX8, PAX2, FOXG1, and SOX2, and subsequently differentiated into hair cell and neuronal lines. This research highlights that mRNA-reprogrammed iPSCs can generate ear lineages similar to those induced by lentivirus, while being safer for potential clinical applications (Boddy et al., 2020).

Presently, there are no Food and Drug Administration (FDA)- approved treatments for cell therapy usage in hearing loss. However, ongoing clinical trials aim to determine the safety and efficacy of cell therapy in treating

hearing loss in humans.

Conclusion

While both endogenous and exogenous stem cell applications have shown promise in various animal models, their translation to human treatments is hindered by several limitations. Addressing these limitations is imperative before considering the implementation of these treatment options in clinical settings. Thus, future studies should prioritize assessing the functional integration of engrafted cells into the intricate hearing system of animal models. Presently, targeted differentiation of stem cells into HCs or neurons, exploration of optimal methods for stem cell transplantation into the inner ear, and rigorous safety evaluations constitute the groundwork for advancing towards clinical cell therapy.

In addressing sensorineural hearing loss (SNHL), conventional treatments such as hearing aids and cochlear implants have been pivotal in improving patients' hearing capabilities. However, the efficacy of these interventions depends on the remaining HCs and spiral neurons. Therefore, current research in audiology emphasizes the development of several approaches aimed at initiating HC regeneration or replacement within the inner ear thereby offering potential solutions for deafness. Although both endogenous and exogenous applications of stem cells have shown promise in several animal models, there are numerous limitations that need addressing before implementing these treatment options in humans. Therefore, further studies should focus on the efficient functional integration of engrafted cells into the hearing systems of animal models. Currently, targeted differentiation of stem cells into HCs or neurons, along with research on methods for stem cell transplantation into the inner ear and their safety, lay the foundation for clinical cell therapy.

Acknowledgement

This work was supported by grant of the Hearing Disorders Research Center of Shahid Beheshti University of Medical Sciences. We would like to appreciate the support of Clinical Research Development Center of Loghman Hakim hospital, Tehran, Iran.

Conflict of Interests

There are no conflicts of interest to declare.

References

- Agterberg MJ, Versnel H, van Dijk LM, de Groot JC, Klis SF. Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs. *JARO* 2009; 10: 355-67. <https://doi.org/10.1007/s10162-009-0170-2>
- Alsina B, Giraldez F, Varela-Nieto I. Growth factors and early development of otic neurons: Interactions between intrinsic and extrinsic signals. *Curr Top Dev Biol* 2003; 57: 177-206. [https://doi.org/10.1016/S0070-2153\(03\)57006-5](https://doi.org/10.1016/S0070-2153(03)57006-5)
- Bader J, Mast-Gerlach E, Popović MK, Bajpai R, Stahl U. Relevance of microbial coculture fermentations in biotechnology. *J Appl Microbiol* 2010; 109: 371-87. <https://doi.org/10.1111/j.1365-2672.2009.04659.x>
- Bakhtiarzadeh F, Nahavandi A, Goudarzi M, Shirvalilou S, Rakhshan K, Niknazar S. Axonal transport proteins and depressive like behavior, following chronic unpredictable mild stress in male rat. *Physiol Behav* 2018; 194: 9-14. <https://doi.org/10.1016/j.physbeh.2018.04.029>
- Baumgartner LS, Moore E, Shook D, Messina S, Day MC, Green J, et al. Safety of autologous umbilical cord blood therapy for acquired sensorineural hearing loss in children. *J Audiol Otol* 2018; 22: 209. <https://doi.org/10.7874/jao.2018.00115>
- Boddy SL, Romero-Guevara R, Ji A-R, Unger C, Corns L, Marcotti W, et al. Generation of otic lineages from integration-free human-induced pluripotent stem cells reprogrammed by mRNAs. *Stem Cell int* 2020; 2020. <https://doi.org/10.1155/2020/3692937>
- Brigande JV, Heller S. Quo vadis, hair cell regeneration? *Nat Neurosci* 2009; 12: 679-85. <https://doi.org/10.1038/nn.2311>
- Carricondo F, Romero-Gómez B. The cochlear spiral ganglion neurons: The auditory portion of the viii nerve. *Anat Rec* 2019; 302: 463-71. <https://doi.org/10.1002/ar.23815>
- Chen J, Hong F, Zhang C, Li L, Wang C, Shi H, et al. Differentiation and transplantation of human induced pluripotent stem cell-derived otic epithelial progenitors in mouse cochlea. *Stem Cell Res Ther* 2018; 9: 1-15. <https://doi.org/10.1186/s13287-018-0967-1>
- Chen W, Jongkamonwiwat N, Abbas L, Eshtan SJ, Johnson SL, Kuhn S, et al. Restoration of auditory evoked responses by human es-cell-derived otic progenitors. *Nature* 2012; 490: 278-82. <https://doi.org/10.1038/nature11415>
- Chen Y. Development and application of co-culture for ethanol production by co-fermentation of glucose and xylose: A systematic review. *J Ind Microbiol Biotechnol* 2011; 38: 581-97. <https://doi.org/10.1007/s10295-010-0894-3>

- Choi BY, Song J-J, Chang SO, Kim SU, Oh SH. Intravenous administration of human mesenchymal stem cells after noise-or drug-induced hearing loss in rats. *Acta oto-laryngologica* 2012; 132: 94-102. <https://doi.org/10.3109/00016489.2012.660731>
- Chuang JS. Engineering multicellular traits in synthetic microbial populations. *Curr Opin Chem Biol* 2012; 16: 370-8. <https://doi.org/10.1016/j.cbpa.2012.04.002>
- Clarke DL, Johansson CB, Wilbertz J, Veress B, Nilsson E, Karlstrom H, et al. Generalized potential of adult neural stem cells. *Science* 2000; 288: 1660-3. <https://doi.org/10.1126/science.288.5471.1660>
- Coleman B, Fallon J, Pettingill L, De Silva M, Shepherd R. Auditory hair cell explant co-cultures promote the differentiation of stem cells into bipolar neurons. *Exp Cell Res* 2007; 313: 232-43. <https://doi.org/10.1016/j.yexcr.2006.10.010>
- Coleman B, Hardman J, Coco A, Epp S, De Silva M, Crook J, et al. Fate of embryonic stem cells transplanted into the deafened mammalian cochlea. *Cell Transplant* 2006; 15: 369-80. <https://doi.org/10.3727/000000006783981819>
- Ding D-C, Shyu W-C, Lin S-Z. Mesenchymal stem cells. *Cell Transplant* 2011; 20: 5-14. <https://doi.org/10.3727/096368910X>
- Dufner-Almeida LG, Cruz DBd, Mingroni RC, Batissoco AC, Oiticica J, Salazar-Silva R. Stem-cell therapy for hearing loss: Are we there yet? *Braz J Otorhinolaryngol* 2019; 85: 520-9. <https://doi.org/10.1016/j.bjorl.2019.04.006>
- Fransson A, Maruyama J, Miller JM, Ulfendahl M. Post-treatment effects of local gdnf administration to the inner ears of deafened guinea pigs. *J Neurotrauma* 2010; 27: 1745-51. <https://doi.org/10.1089/neu.2009.1218>
- Gage FH. Mammalian neural stem cells. *Science* 2000; 287: 1433-1438. <https://doi.org/10.1126/science.287.5457.1433>
- Gillespie LN, Shepherd RK. Clinical application of neurotrophic factors: The potential for primary auditory neuron protection. *Eur J Neurosci* 2005; 22: 2123-33. <https://doi.org/10.1111/j.1460-9568.2005.04430.x>
- Goers L, Freemont P, Polizzi KM. Co-culture systems and technologies: Taking synthetic biology to the next level. *J R Soc Interface* 2014; 11: 20140065. <https://doi.org/10.1098/rsif.2014.0065>
- Gökcan MK, Mülazimoğlu S, Ocak E, Can P, ÇALIŞKAN M, BEŞALTI Ö, et al. Study of mouse induced pluripotent stem cell transplantation into wistar albino rat cochlea after hair cell damage. *Turk J Med Sci* 2016; 46: 1603-10. <https://doi.org/10.3906/sag-1510-136>
- Gonmanee T, Thonabulsombat C, Vongsavan K, Sritanau-domchai H. Differentiation of stem cells from human deciduous and permanent teeth into spiral ganglion neuron-like cells. *Arch Oral Biol* 2018; 88: 34-41. <https://doi.org/10.1016/j.archoralbio.2018.01.011>
- Guadix JA, Zugaza JL, Gálvez-Martín P. Characteristics, applications and prospects of mesenchymal stem cells in cell therapy. *Med Clin* 2017; 148: 408-14. <https://doi.org/10.1016/j.medcli.2016.11.033>
- Gunewardene N, Bergen NV, Crombie D, Needham K, Dottori M, Nayagam BA. Directing human induced pluripotent stem cells into a neurosensory lineage for auditory neuron replacement. *BioResearch Open Access* 2014; 3: 162-75. <https://doi.org/10.1089/biores.2014.0019>
- Hildebrand MS, Dahl H-HM, Hardman J, Coleman B, Shepherd RK, De Silva MG. Survival of partially differentiated mouse embryonic stem cells in the scala media of the guinea pig cochlea. *Journal of the Association for Research in Otolaryngology* 2005; 6: 341-54. <https://doi.org/10.1007/s10162-005-0012-9>
- Hu Z, Wei D, Johansson CB, Holmström N, Duan M, Frisén J, et al. Survival and neural differentiation of adult neural stem cells transplanted into the mature inner ear. *Exp Cell Res* 2005; 302: 40-7. <https://doi.org/10.1016/j.yexcr.2004.08.023>
- Hyakumura T, McDougall S, Finch S, Needham K, Dottori M, Nayagam BA. Organotypic cocultures of human pluripotent stem cell derived-neurons with mammalian inner ear hair cells and cochlear nucleus slices. *Stem Cell Int* 2019; 2019. <https://doi.org/10.1155/2019/8419493>
- Ishikawa M, Ohnishi H, Skerleva D, Sakamoto T, Yamamoto N, Hotta A, et al. Transplantation of neurons derived from human ips cells cultured on collagen matrix into guinea-pig cochlea. *J Tissue Eng Regen Med* 2017; 11: 1766-78. <https://doi.org/10.1002/term.2072>
- Ito J, Kojima K, Kawaguchi S. Survival of neural stem cells in the cochlea. *Acta oto-laryngologica* 2001; 121: 140-2. <https://doi.org/10.1080/000164801300043226>
- Izumikawa M, Minoda R, Kawamoto K, Abrashkin KA, Swiderski DL, Dolan DF, et al. Auditory hair cell replacement and hearing improvement by *atoh1* gene therapy in deaf mammals. *Nat Med* 2005; 11: 271-6. <https://doi.org/10.1038/nm1193>
- Jeon S-J, Oshima K, Heller S, Edge AS. Bone marrow mesenchymal stem cells are progenitors in vitro for inner ear hair cells. *Mol Cell Neurosci* 2007; 34: 59-68. <https://doi.org/10.1016/j.mcn.2006.10.003>
- Kamiya K, Fujinami Y, Hoya N, Okamoto Y, Kouike H,

- Komatsuzaki R, et al. Mesenchymal stem cell transplantation accelerates hearing recovery through the repair of injured cochlear fibrocytes. *Am J Pathol* 2007; 171: 214-26. <https://doi.org/10.2353/ajpath.2007.060948>
- Kandel ER, Schwartz JH, Jessell TM, Siegelbaum S, Hudspeth AJ, Mack S. Principles of neural science. Vol 4: McGraw-hill New York, 2000.
- Kasagi H, Kuhara T, Okada H, Sueyoshi N, Kurihara H. Mesenchymal stem cell transplantation to the mouse cochlea as a treatment for childhood sensorineural hearing loss. *Int J Pediatr Otorhinolaryngol* 2013; 77: 936-42. <https://doi.org/10.1016/j.ijporl.2013.03.011>
- Kelley MW. Regulation of cell fate in the sensory epithelia of the inner ear. *Nat Rev Neurosci* 2006; 7: 837-49. <https://doi.org/10.1038/nrn1987>
- Khoshsirat S, Abbaszadeh H-A, Peyvandi AA, Heidari F, Peyvandi M, Simani L, et al. Apelin-13 prevents apoptosis in the cochlear tissue of noise-exposed rat via sirt-1 regulation. *J Chem Neuroanat* 2021; 114: 101956. <https://doi.org/10.1016/j.jchemneu.2021.101956>
- Kil K, Choi MY, Park KH. In vitro differentiation of human wharton's jelly-derived mesenchymal stem cells into auditory hair cells and neurons. *J Int Adv Otol* 2016; 12: 37. <https://doi.org/10.5152/iao.2016.1190>
- Koehler KR, Mikosz AM, Molosh AI, Patel D, Hashino E. Generation of inner ear sensory epithelia from pluripotent stem cells in 3d culture. *Nature* 2013; 500: 217-21. <https://doi.org/10.1038/nature12298>
- Krinner A, Roeder I. Quantification and modeling of stem cell-niche interaction. *A Systems Biology Approach to Blood* 2014: 11-36. https://doi.org/10.1007/978-1-4939-2095-2_2
- Lang H, Schulte BA, Goddard JC, Hedrick M, Schulte JB, Wei L, et al. Transplantation of mouse embryonic stem cells into the cochlea of an auditory-neuropathy animal model: Effects of timing after injury. *Journal of the Association for Research in Otolaryngology* 2008; 9: 225-40. <https://doi.org/10.1007/s10162-008-0119-x>
- Lee HS, Kim WJ, Gong JS, Park KH. Clinical safety and efficacy of autologous bone marrow-derived mesenchymal stem cell transplantation in sensorineural hearing loss patients. *J Audiol Otol* 2018; 22: 105. <https://doi.org/10.7874/jao.2017.00150>
- Li H, Corrales CE, Edge A, Heller S. Stem cells as therapy for hearing loss. *Trends Mol Med* 2004; 10: 309-15. <https://doi.org/10.1016/j.molmed.2004.05.008>
- Li H, Liu H, Heller S. Pluripotent stem cells from the adult mouse inner ear. *Nat Med* 2003a; 9: 1293-9. <https://doi.org/10.1038/nm925>
- Li H, Roblin G, Liu H, Heller S. Generation of hair cells by stepwise differentiation of embryonic stem cells. *Proc Natl Acad Sci U S A* 2003b; 100: 13495-500. <https://doi.org/10.1073/pnas.2334503100>
- Lopez-Juarez A, Lahlou H, Ripoll C, Cazals Y, Brezun JM, Wang Q, et al. Engraftment of human stem cell-derived otic progenitors in the damaged cochlea. *Mol Ther* 2019; 27: 1101-13. <https://doi.org/10.1016/j.ymthe.2019.03.018>
- Lou X, Yuan H, Xie J, Wang X, Yang L, Zhang Y. Growth factors have a protective effect on neomycin-induced hair cell loss. *Cell Biol Int* 2015; 39: 65-73. <https://doi.org/10.1002/cbin.10347>
- Mahmoudian-Sani M-R, Hashemzadeh-Chaleshtori M, Jami M-S, Saidijam M. In vitro differentiation of human bone marrow mesenchymal stem cells to hair cells using growth factors. *Int Tinnitus J* 2017; 21: 179-84. <https://doi.org/10.5935/0946-5448.20170030>
- Mahmoudian-Sani M-R, Jamshidi M, Asgharzade S. Combined growth factor and gene therapy: An approach for hair cell regeneration and hearing recovery. *ORL* 2018; 80: 326-37. <https://doi.org/10.1159/000493011>
- Maruyama J, Miller JM, Ulfendahl M. Glial cell line-derived neurotrophic factor and antioxidants preserve the electrical responsiveness of the spiral ganglion neurons after experimentally induced deafness. *Neurobiol Dis* 2008; 29: 14-21. <https://doi.org/10.1016/j.nbd.2007.07.026>
- Menendez L, Trecek T, Gopalakrishnan S, Tao L, Markowitz AL, Haoze VY, et al. Generation of inner ear hair cells by direct lineage conversion of primary somatic cells. *Elife* 2020; 9: e55249. <https://doi.org/10.7554/eLife.55249>
- Mittal R, Ocak E, Zhu A, Perdomo MM, Pena SA, Mittal J, et al. Effect of bone marrow-derived mesenchymal stem cells on cochlear function in an experimental rat model. *Anat Rec* 2020; 303: 487-93. <https://doi.org/10.1002/ar.24065>
- Momeni B, Chen C-C, Hillesland KL, Waite A, Shou W. Using artificial systems to explore the ecology and evolution of symbioses. *Cell Mol Life Sci* 2011; 68: 1353-68. <https://doi.org/10.1007/s00018-011-0649-y>
- Nakagawa T. Strategies for developing novel therapeutics for sensorineural hearing loss. *Front Pharmacol* 2014; 5: 206. <https://doi.org/10.3389/fphar.2014.00206>
- Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripotent stem cells: Developmental biology to regenerative medicine. *Nat Rev Cardiol* 2010; 7: 700-10. <https://doi.org/10.1038/nrcardio.2010.159>

- Niemeyer P, Salzman G, Hirschmüller A, Südkamp N. Factors that influence clinical outcome following autologous chondrocyte implantation for cartilage defects of the knee. *Z Orthop Unfall Unfallchirurgie* 2011; 150: 83-8. <https://doi.org/10.1055/s-0030-1270894>
- Niknazar S, Abbaszadeh H-A, Khoshsirat S, Mehrjerdi FZ, Peyvandi AA. Combined treatment of retinoic acid with olfactory ensheathing cells protect gentamicin-induced sngns damage in the rat cochlea in vitro. *Mol Cel Neurosci* 2022; 121: 103752. <https://doi.org/10.1016/j.mcn.2022.103752>
- Niknazar S, Abbaszadeh H-A, Peyvandi H, Rezaei O, Forooghiraad H, Khoshsirat S, et al. Protective effect of [pyr1]-apelin-13 on oxidative stress-induced apoptosis in hair cell-like cells derived from bone marrow mesenchymal stem cells. *Eur J Pharmacol* 2019; 853: 25-32. <https://doi.org/10.1016/j.ejphar.2019.03.012>
- Nishimura K, Nakagawa T, Ono K, Ogita H, Sakamoto T, Yamamoto N, et al. Transplantation of mouse induced pluripotent stem cells into the cochlea. *Neuroreport* 2009; 20: 1250-4. <https://doi.org/10.1097/WNR.0b013e32832ff287>
- Noback CR. The human nervous system: Basic elements of structure and function: Blakiston Division, McGraw-Hill, 1967.
- Nourbakhsh A, Colbert BM, Nisenbaum E, El-Amraoui A, Dykxhoorn DM, Koehler KR, et al. Stem cells and gene therapy in progressive hearing loss: The state of the art. *Journal of the Association for Research in Otolaryngology* 2021; 22: 95-105. <https://doi.org/10.1007/s10162-020-00781-0>
- Okano T, Kelley MW. Stem cell therapy for the inner ear: Recent advances and future directions. *Trends Amplif* 2012; 16: 4-18. <https://doi.org/10.1177/1084713812440336>
- Okano T, Nakagawa T, Endo T, Kim T-S, Kita T, Tamura T, et al. Engraftment of embryonic stem cell-derived neurons into the cochlear modiolus. *Neuroreport* 2005; 16: 1919-22. <https://doi.org/10.1097/01.wnr.0000187628.38010.5b>
- Ortiz-Marquez JCF, Do Nascimento M, Zehr JP, Curatti L. Genetic engineering of multispecies microbial cell factories as an alternative for bioenergy production. *Trends Biotech* 2013; 31: 521-9. <https://doi.org/10.1016/j.tibtech.2013.05.006>
- Oshima K, Grimm CM, Corrales CE, Senn P, Martinez Monedero R, Géléoc GS, et al. Differential distribution of stem cells in the auditory and vestibular organs of the inner ear. *JARO* 2007; 8: 18-31. <https://doi.org/10.1007/s10162-006-0058-3>
- Oshima K, Shin K, Diensthuber M, Peng AW, Ricci AJ, Heller S. Mechanosensitive hair cell-like cells from embryonic and induced pluripotent stem cells. *Cell* 2010; 141: 704-16. <https://doi.org/10.1016/j.cell.2010.03.035>
- Palmgren B, Jiao Y, Novozhilova E, Stupp SI, Olivius P. Survival, migration and differentiation of mouse tau-gfp embryonic stem cells transplanted into the rat auditory nerve. *Exp Neurolog* 2012; 235: 599-609. <https://doi.org/10.1016/j.expneurol.2012.03.014>
- Parker MA, Corliss DA, Gray B, Anderson JK, Bobbin RP, Snyder EY, et al. Neural stem cells injected into the sound-damaged cochlea migrate throughout the cochlea and express markers of hair cells, supporting cells, and spiral ganglion cells. *Hear Res* 2007; 232: 29-43. <https://doi.org/10.1016/j.heares.2007.06.007>
- Pettingill LN, Wise AK, Geaney MS, Shepherd RK. Enhanced auditory neuron survival following cell-based bdnf treatment in the deaf guinea pig. *PloS One* 2011; 6: e18733. <https://doi.org/10.1371/journal.pone.0018733>
- Peyvandi A, Abbaszadeh HA, Roozbahany NA, Pourbakht A, Khoshsirat S, Niri HH, et al. Deferoxamine promotes mesenchymal stem cell homing in noise-induced injured cochlea through pi 3k/akt pathway. *Cell Prolif* 2018a; 51: e12434. <https://doi.org/10.1111/cpr.12434>
- Peyvandi AA, Roozbahany NA, Peyvandi H, Abbaszadeh H-A, Majdinasab N, Faridan M, et al. Critical role of sdf-1/cxcr4 signaling pathway in stem cell homing in the deafened rat cochlea after acoustic trauma. *Neural Regen Res* 2018b; 13: 154. <https://doi.org/10.4103/1673-5374.224382>
- Qin H, Zhao L-D, Sun J-H, Ren L-L, Guo W-W, Liu H-Z, et al. The differentiation of mesenchymal stem cells into inner ear hair cell-like cells in vitro. *Acta oto-laryngologica* 2011; 131: 1136-41. <https://doi.org/10.3109/00016489.2011.603135>
- Ramsden RT. Cochlear implants and brain stem implants. *Br Med Bull* 2002; 63: 183-93. <https://doi.org/10.1093/bmb/63.1.183>
- Ronaghi M, Nasr M, Ealy M, Durruthy-Durruthy R, Waldhaus J, Diaz GH, et al. Inner ear hair cell-like cells from human embryonic stem cells. *Stem Cells Dev* 2014; 23: 1275-84. <https://doi.org/10.1089/scd.2014.0033>
- Sambandam S. Does stem cell regenerative medicine could provide good clinical outcome for deafness?-the focus on current difficulties on clinical application. *Trends tech sci res* 2018; 2: 41-7. <https://doi.org/10.19080/TTSR.2018.02.555586>
- Shepherd RK, Coco A, Epp SB. Neurotrophins and electrical stimulation for protection and repair of spiral ganglion neu-

- rons following sensorineural hearing loss. *Hear Res* 2008; 242: 100-9. <https://doi.org/10.1016/j.heares.2007.12.005>
- Shi F, Corrales CE, Liberman MC, Edge AS. Bmp4 induction of sensory neurons from human embryonic stem cells and reinnervation of sensory epithelium. *Eur J Neurosci* 2007; 26: 3016-23. <https://doi.org/10.1111/j.1460-9568.2007.05909.x>
- Shinohara T, Bredberg G, Ulfendahl M, Pyykkö I, Olivius NP, Kaksonen R, et al. Neurotrophic factor intervention restores auditory function in deafened animals. *Proc Natl Acad Sci U S A* 2002; 99: 1657-60. <https://doi.org/10.1073/pnas.032677999>
- Sprinzel G, Riechelmann H. Current trends in treating hearing loss in elderly people: A review of the technology and treatment options-a mini-review. *Gerontology* 2010; 56: 351-8. <https://doi.org/10.1159/000275062>
- Suzuki M, Yagi M, Brown JN, Miller AL, Miller JM, Raphael Y. Effect of transgenic GDNF expression on gentamicin-induced cochlear and vestibular toxicity. *Gene Therapy*. 2000 Jun;7(12):1046-54.
- Steel KP, Kros CJ. A genetic approach to understanding auditory function. *Nat Genet* 2001; 27: 143-9. <https://doi.org/10.1038/84758>
- Tamura T, Nakagawa T, Iguchi F, Tateya I, Endo T, Kim T, et al. Transplantation of neural stem cells into the modiolus of mouse cochleae injured by cisplatin. *Acta Otolaryngologica SUPPLEMENTUM* 2004: 65-8. <https://doi.org/10.1080/03655230310016780>
- Warchol ME, Lambert PR, Goldstein BJ, Forge A, Corwin JT. Regenerative proliferation in inner ear sensory epithelia from adult guinea pigs and humans. *Science* 1993; 259: 1619-22. <https://doi.org/10.1126/science.8456285>
- Wu T, Liu Y, Wang B, Li G. The roles of mesenchymal stem cells in tissue repair and disease modification. *Curr Stem Cell Res Ther* 2014; 9: 424-31. <https://doi.org/10.2174/1574888X09666140616125446>
- Xu Y-p, Shan X-d, Liu Y-y, Pu Y, Wang C-y, Tao Q-l, et al. Olfactory epithelium neural stem cell implantation restores noise-induced hearing loss in rats. *Neurosci Lett* 2016; 616: 19-25. <https://doi.org/10.1016/j.neulet.2016.01.016>
- Yoo T, Du X, Zhou B. The paracrine effect of mesenchymal human stem cells restored hearing in β -tubulin induced autoimmune sensorineural hearing loss. *Hear Res* 2015; 330: 57-61. <https://doi.org/10.1016/j.heares.2015.07.021>
- Young E, Westerberg B, Yanai A, Gregory-Evans K. The olfactory mucosa: A potential source of stem cells for hearing regeneration. *Regen Med* 2018; 13: 581-93. <https://doi.org/10.2217/rme-2018-0009>
- Yu J, Thomson JA. Induced pluripotent stem cells. *Principles of tissue engineering*: Elsevier, 2014: 581-94. <https://doi.org/10.1016/B978-0-12-398358-9.00030-6>
- Zengler K, Toledo G, Rappé M, Elkins J, Mathur EJ, Short JM, et al. Cultivating the uncultured. *Proc Natl Acad Sci U S A* 2002; 99: 15681-6. <https://doi.org/10.1073/pnas.252630999>
- Zheng JL, Gao W-Q. Overexpression of *math1* induces robust production of extra hair cells in postnatal rat inner ears. *Nat Neurosci* 2000; 3: 580-6. <https://doi.org/10.1038/75753>
- Zine A, Nyffeler M, De Ribaupierre F. Spatial expression patterns of epidermal growth factor receptor gene transcripts in the postnatal mammalian cochlea. *Hear Res* 2000; 141: 19-27. [https://doi.org/10.1016/S0378-5955\(99\)00203-8](https://doi.org/10.1016/S0378-5955(99)00203-8)